Accelerating Cell And Gene Therapy Development With Excipient GMP Quality Media And Buffers: The Nucleus Biologics Advantage

By Brad N. Taylor, Ph.D.

The success of groundbreaking cell and gene therapy treatments hinges on meticulous manufacturing processes, where excipients – non-active ingredients – play a critical role. These often-overlooked components ensure the stability, consistency, and functionality of CGT products.

Nucleus Biologics recognizes the crucial role of excipients in CGT development. Our recent EXCiPACT and ISO 9001 certifications underscore our commitment to providing GMP-quality excipients that meet stringent regulatory requirements. These certifications guarantee the highest standards of quality, safety, and supply chain integrity, ensuring consistent and reliable performance throughout the CGT product lifecycle.

By choosing Nucleus Biologics' Excipient GMP materials, CGT developers can streamline regulatory filings, ensure seamless transitions from research to commercial manufacturing, and ultimately accelerate patient access to life-saving therapies. Continue reading to learn more about the Nucleus Biologics advantage and how our commitment to quality empowers CGT innovation.